Skip to content

Kura Oncology KURA Enterprise value

Enterprise value at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$622.06B+50.5%
Amgen logo
AmgenAMGN
$246.43B+9.9%
Exelixis logo
ExelixisEXEL
$11.24B+9.5%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$2.28B+84.0%
AbbVie logo
AbbVieABBV
$460.96B+24.7%
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
$1.19B+459%

Other financials

Income statement

See full
Revenue$18.3M+29.5%
Gross profit$18.0M
Operating income-$78.8M-21.8%
Net income-$73.3M-27.7%
EPS (diluted)-$0.83-25.8%

Balance sheet

See full
Cash & equivalents$39.1M-23.8%
Total debt$24.3M+25.4%
Total equity$107.9M-70.4%
Total assets$652.6M-12.3%

Cash flow

See full
Operating cash flow-$85.9M-19.4%
CapEx$128.0K-56.2%
Free cash flow-$86.0M-19.1%

Valuation

See full
Market cap$942.78M+86.2%
P/S13.2×+3.9×

Profitability

See full
Operating margin-443.5%+103pp
Net margin-411.2%+125pp
FCF margin130.6%+74.1pp

Returns & leverage

See full
Return on equity-124.7%-252pp
Debt / equity0.2×+0.2×
Current ratio6.1×-1.9×

Where this comes from

Calculated from Kura Oncology’s reported figures.

The official record: Kura Oncology’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kura Oncology's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kura Oncology's enterprise value?
Kura Oncology (KURA) reported enterprise value of $703.31M in Q1 2026.
How has Kura Oncology's enterprise value changed year-over-year?
Kura Oncology's enterprise value increased by 40.4% year-over-year, from $501.07M to $703.31M.
What is the long-term trend for Kura Oncology's enterprise value?
Over 5 years (2020 to 2025), Kura Oncology's enterprise value has grown at a -16.0% compound annual growth rate (CAGR), from $1.85B to $775.47M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.